Graham Nicholls of Almac Group to Speak on Adaptive Trial Designs and Clinical Supplies at CTS Europe Conference

SOUDERTON, Pennsylvania, February 14, 2011 - The Almac Group announced today that Graham Nicholls, Director of
Biostatistics for Almac's Clinical Technologies business unit, will be
speaking at the Clinical Trial Supply Europe conference (CTS Europe) held in
Barcelona, Spain, 22-23 February 2011. The conference will be attended by two
of Almac's business units directly involved with providing an integrated
clinical supply chain solution involving IXRS(R) technology, planning,
forecasting, packaging, labeling, analytical testing, inventory management,
and global distribution of supplies for clinical trials.

Graham Nicholls plans to speak on the topic of the challenges of
conducting adaptive trials. A notable expert on this subject, Mr. Nicholls
will provide an overview of adaptive trial designs and comment on some of the
current regulatory and logistical perspectives of implementing such trials on
a global basis. Additionally, Mr. Nicholls will address some of the
particular challenges that adaptive trial designs have on clinical supplies
planning, as well as on manufacturing, packaging, and IXRS(R) technology
considerations.

Jim Murphy, President of Almac's Clinical Technologies Business unit
comments on the unique full service clinical supply solution offered by
Almac: "Graham's knowledge of dynamic randomization strategies has helped
Almac solidify its reputation as an industry leader in adaptive and other
complex trial designs. Graham's knowledge complements Almac's logistical
expertise in managing clinical supply chains on a global basis, providing our
clients with a full-service drug supply management solution for adaptive
trials that is unmatched in our industry. As we are seeing an increasing
number of adaptive trials, it is important to share Graham's extensive
knowledge at conferences, such as CTS Europe, to help sponsors plan and
execute on complex study designs."

Almac will be showcasing its integrated technology and clinical supply
chain solution at booth #19 at the CTS Europe show.

About Almac Group

The Almac Group provides a broad range of services from R&D, biomarker
discovery and development, API manufacture, formulation development, clinical
trial supply and IXRS technology (IVRS/IWRS), to commercial-scale
manufacture. Almac provides services to more than 600 companies, including
all the world leaders in the pharmaceutical and biotech sectors.

The company employs over 3,000 individuals and is headquartered in
Craigavon, Northern Ireland. US operations are based in Pennsylvania, North
Carolina and California. Almac has now moved into its new $120m North
American Headquarters located in Souderton PA.

Almac's Clinical Technologies business unit specializes in interactive
technology and service solutions to increase the quality and efficiency of
clinical trials. Our solutions include Interactive Voice and Web Response
Systems (IXRS(R)) for patient randomization and drug assignment, patient and
clinical supplies management, electronic-patient-reported-outcomes data
collection, and Web drug reconciliation. Almac's technologies have been
deployed in over 1600 clinical trials, incorporating over 1.5 million
patients in over 80 countries, and more than 60 languages.

For more information about the Almac Group, please visit
www.almacgroup.com

Contact: Joseph Bedford, PhD, T: +1-215-660-8500, E: clinicaltechnologies at almacgroup.com. Tristan Jervis, DeFacto, T.Jervis at Defacto.com, Tel: +44(0)20-7861-3019, or e-mail info at almacgroup.com